Press Releases

 Filter by Provider

York Space Systems Inc. (NYSE: YSS) will release its financial results for the quarter and full year ended December 31, 2025 after the close of market on Thursday, March 19, 2026. In conjunction with this release, York will host a conference call to review its financial results for the quarter and the year, discuss its outlook for the future and may disclose other material developments affecting its business and/or financial performance. Listeners may access the conference call live via an audio webcast.

DWS Municipal Income Trust (KTF) (the “Fund”) announced today its regular March monthly distribution.

OPAL Fuels (Nasdaq: OPAL) announced that it has closed a new $180 million preferred stock facility with an affiliate of its majority shareholder, Fortistar. At closing, $120 million was issued from the facility, of which approximately $100 million was used to fully redeem the Series A Preferred Units previously owned by Mendocino Capital, LLC. The remaining $60 million of the facility will be available for future draw-downs.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the fourth quarter 2025 and provide a business update on March 12, 2026.

Uncovering Hidden Dangers: Essential Buyer Inspections for Historic Homes

How Local SEO Agency is Transforming Technical SEO and Backlink Building Across South Africa

W. R. Berkley Corporation (NYSE: WRB) today announced the appointment of Ryan Miller as president of Berkley Southeast. The appointment is effective immediately.

Essential Properties Realty Trust, Inc. (NYSE: EPRT; the “Company”) announced today that its Board of Directors declared a quarterly cash dividend of $0.31 per share of common stock for the first quarter of 2026. On an annualized basis, the first quarter 2026 dividend of $0.31 equals $1.24 per share of common stock. The dividend is payable on April 14, 2026, to stockholders of record as of the close of business on March 31, 2026.

The Board of Directors of DNP Select Income Fund Inc. (NYSE: DNP), a closed-end fund advised by Duff & Phelps Investment Management Co. (the “Adviser”), previously announced the following monthly distribution on December 11, 2025:

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Fluent, Inc. (NASDAQ: FLNT), a commerce media solutions company, today reported unaudited results for the fourth quarter and fiscal year ended December 31, 2025. These results are preliminary and subject to ongoing audit procedures.

Dallas, Texas, March 09, 2026 (GLOBE NEWSWIRE) -- Kronos Worldwide, Inc. (NYSE:KRO) today reported a net loss of $82.8 million, or $.72 per share, in the fourth quarter of 2025 compared to a net loss of $13.2 million, or $.12 per share, in the fourth quarter of 2024. For the full year of 2025, Kronos Worldwide reported a net loss of $110.9 million, or $.96 per share, compared to net income of $86.2 million, or $.75 per share, for the full year of 2024. Our net loss increased in the fourth quarter of 2025 compared to the fourth quarter of 2024 due to lower income from operations primarily due to higher unabsorbed fixed production costs resulting from production curtailments and lower average TiO2 selling prices somewhat offset by higher sales volumes. In addition, we recorded non-cash deferred income tax expense of $8.5 million ($.07 per share) related to the recognition of a valuation allowance on our German net deferred tax asset. Our net loss increased in the full year of 2025 compared to the full year of 2024 primarily due to higher unabsorbed fixed production costs resulting from production curtailments, lower average TiO2 selling prices, and higher distribution and warehousing costs. The increase in distribution and warehousing costs was primarily in the first quarter of 2025, when we positioned finished goods inventory in the U.S. in response to anticipated U.S. federal government tariff announcements. The full year of 2025 also included non-cash deferred income tax expense of $19.3 million ($.17 per share) related to German tax legislation enacted in the third quarter of 2025 and the fourth quarter recognition of a valuation allowance related to our German net deferred tax asset, as noted above. Comparability of our results are also impacted by the effects of changes in currency exchange rates. As previously reported, effective July 16, 2024, we acquired the 50% joint venture interest in Louisiana Pigment Company, L.P. (“LPC”) previously held by Venator Investments, Ltd. Prior to the acquisition, we held a 50% joint venture interest in LPC. Following the acquisition, LPC became a wholly-owned subsidiary of ours. In 2025, LPC merged into our wholly-owned subsidiary Kronos Louisiana, Inc. We accounted for the acquisition as a business combination. The results of operations of LPC have been included in our results of operations beginning as of the acquisition date. Net income for the full year of 2024 includes the recognition of a non-cash gain of $64.5 million ($50.9 million, or $.44 per share, net of income tax expense) associated with the remeasurement of our investment in LPC as a result of the acquisition.

CRANFORD, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”) today announced that it has extended the expiration date for the exchange offer by the Company to each holder of its Series C Non-Convertible Redeemable Preferred Stock, $0.01 par value per share (the “Series C Preferred Stock”), to exchange such Series C Preferred Stock for shares of Enzon’s common stock, $0.01 par value per share (the “Common Stock”). After giving effect to the extension, the offer expires one minute after 11:59 p.m., Eastern Time, on March 11, 2026, unless the offer is further extended.

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Apollo Commercial Real Estate Finance, Inc. (the “Company”) (NYSE:ARI) today announced the Board of Directors declared a dividend of $0.25 per share of common stock, which is payable on April 15, 2026 to common stockholders of record on March 31, 2026.

– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 –

National Aviation Center is helping aircraft owners, pilots, and aviation professionals manage essential documentation requirements through a streamlined online platform designed to simplify aircraft registration services. By offering guidance on aircraft identification, registration records, and important filing documents, the organization aims to make the regulatory process more accessible for individuals navigating federal aviation requirements.

Corporation Center is expanding access to online resources designed to help entrepreneurs and business owners navigate company formation and regulatory compliance across the United States. Through its digital platform, the service provides guidance on business registration, corporate filings, and commonly asked tax questions such as do LLP get 1099, while also assisting companies seeking to register foreign LLC in Massachusetts and other states.

New York-based scholar Mara Naaman urges educators, writers, and families to move beyond "success metrics" and reconnect with learning, art, and human connection.

Company advances Albany Graphite relationships across federal, provincial, and community levels

Columbia, South Carolina--(Newsfile Corp. - March 9, 2026) - Elauwit Connection, Inc. (NASDAQ: ELWT) ("Elauwit" or the "Company"), a national...

The Board of Directors of Duff & Phelps Utility and Infrastructure Fund Inc. (NYSE: DPG), a closed-end fund advised by Duff & Phelps Investment Management Co., previously announced the following monthly distribution on December 11, 2025:

United Natural Foods, Inc. (NYSE: UNFI) will participate in this year’s UBS Global Consumer and Retail Conference. President and Chief Financial Officer, Matteo Tarditi, will be part of a fireside chat beginning at 8:00 am Eastern Time on March 12, 2026.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025.

Agency reserves federally guaranteed lending for American citizens

Shift4 (NYSE: FOUR), the leader in integrated payments and commerce technology, today announced several key promotions and leadership changes.

The long‑held notion that “it takes a village” to raise a family feels increasingly out of reach for today’s working parents and was the focus of the first wave of research in the 2026 Modern Family Index (MFI) research study, commissioned by Bright Horizons Family Solutions, Inc. (NYSE: BFAM) and conducted by The Harris Poll.

Repay Holdings Corporation (NASDAQ: RPAY) (“REPAY” or the “Company”), a leading provider of vertically-integrated payment solutions, today reported financial results for its fourth quarter and full year ended December 31, 2025.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced today it has entered into its first among a series of expected network participation agreements with Elevance Health. The contracts, which include the Anthem-affiliated Commercial, Medicare Advantage, and Medicaid plans are expected to become effective on a market-by-market basis through the second quarter of 2026. Once complete, the addition of these 45 million medical members will bring Myomo’s total number of covered lives under commercial insurance plans to over 80 million.

Nu Skin Enterprises Inc. (NYSE:NUS) today announced the appointment of Chayce Clark as chief operating officer effective immediately. Clark will be responsible for leading the company’s revenue performance and end-to-end operational execution across the business in addition to maintaining his role as the company’s chief legal officer.

Yext, Inc. (NYSE: YEXT), the leading digital presence platform for multi-location brands, today announced its results for the three months ended January 31, 2026, or Yext's fourth quarter, and the fiscal year ended January 31, 2026.

ATLANTA, March 09, 2026 (GLOBE NEWSWIRE) -- Bitcoin Depot (Nasdaq: BTM) (“Bitcoin Depot” or the “Company”), a U.S.-based Bitcoin ATM (“BTM”) operator and leading fintech company, will hold a conference call and live audio webcast on Monday, March 16th at 10:00 a.m. Eastern time (7:00 a.m. Pacific time) to discuss its financial results for the fourth quarter and full year ended December 31, 2025. Bitcoin Depot plans to release its results before the market opens on the same day.

Prothena Corporation plc (NASDAQ:PRTA) today announced that the Company earned a $50 million milestone payment from Novo Nordisk related to the achievement of a prespecified enrollment target in the ongoing Phase 3 CLEOPATTRA clinical trial evaluating coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody, for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM).

HPE (NYSE: HPE) today announced financial results for the first quarter ended January 31, 2026.

Transcat, Inc. (Nasdaq: TRNS) (“Transcat” or the “Company”), a leader in test measurement, control and calibration, today announced the appointment of Jaime Irick as President and Chief Executive Officer, effective March 29, 2026. The Board also appointed Mr. Irick to the Transcat Board of Directors as of March 29, 2026, where he will serve on the Executive Committee. As previously announced, Lee D. Rudow is retiring from his role as CEO and from the Board, and will be a senior advisor to the Company through March 2027.

HOUSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Amplify Energy Corp. (NYSE: AMPY) (“Amplify,” the “Company,” “us,” or “our”) announced today updates to its strategic initiatives, year-end 2025 proved reserves, operating and financial results for the fourth quarter and full-year 2025, and full-year 2026 development plans and guidance for the Company.

Net Asset Value of $8.09 Per Share as of December 31, 2025

Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 

SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- The RealReal, Inc. (Nasdaq: REAL), the world’s largest online marketplace for authenticated luxury resale, today announced changes to its Board of Directors and executive leadership team, further strengthening the Company’s governance and operational leadership as it advances its next phase of growth.

Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Driven Brands Holdings Inc. (NASDAQ:DRVN) and certain of the Company’s senior executives for securities fraud after the Company disclosed widespread accounting errors and internal control failures, causing its stock to drop nearly 40%.

Wisk Aero, an autonomous aviation company, today celebrates the U.S. Department of Transportation’s (DOT) and the Federal Aviation Administration’s (FAA) selection of the Texas Department of Transportation (TxDOT) for the Electric Vertical Takeoff and Landing (eVTOL) and Advanced Air Mobility (AAM) Integration Pilot Program (eIPP).

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN).

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of (i) options to purchase an aggregate of 134,540 common shares of the Company (the "Options") and (ii) 34,500 performance share units (the “PSUs”) (assuming achievement at target levels of performance) that, if earned, will be settled in Definium common shares upon vesting, with effective grant dates of February 24, 2026, February 27, 2026 and March 9, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee’s continued employment. The PSUs will vest on the third anniversary of the grant date, subject to continued service through the vesting date. Actual earned PSUs can range from 0%-200% of the target number of PSUs and will be based on the achievement of certain performance metrics as measured at the end of the three-year performance period.

Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026

VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that it has commenced an underwritten public offering of $500.0 million of its common shares, pursuant to its existing shelf registration statement. All of the common shares in this offering are being offered by Xenon. In addition, Xenon intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $75.0 million of common shares at the public offering price, less the underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced an inducement grant for Matthew Greenhawt, MD, MBA, MSc, Chief Medical Officer of Aquestive Therapeutics (the “Company”), under the Company’s 2022 Equity Inducement Plan. The inducement grant was approved by the Company’s Compensation Committee.

MITCHEL FIELD, N.Y., March 09, 2026 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (NASDAQ: FEIM), will hold a conference call to discuss results for the third quarter of its fiscal year 2026, ended January 31, 2026, on Wednesday, March 11, 2026, at 4:30 PM Eastern Time.

NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it has commenced an underwritten public offering of $400 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Dianthus expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Dianthus.

WATERTOWN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on March 9, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).

AUSTIN, TX / ACCESS Newswire / March 9, 2026 / Managing chronic muscle tension and daily aches is one of the most persistent challenges for maintaining a high quality of life. Failing to address deep muscle pain or persistent cramps can leave someone feeling drained, restricted in their movement, and unable to focus on daily tasks. Many people are searching for a solution that goes beyond temporary relief. They want a way to recover faster, soothe tension instantly, and regain their physical comfort without relying on constant medication.

PHOENIX, AZ / ACCESS Newswire / March 9, 2026 / As organizations across public safety, infrastructure, and large asset-heavy operations increasingly rely on real-time data to drive faster, safer decisions, Rapid Drone has officially launched as a specialized aerial intelligence and drone services provider. The company enters the market amid rapid growth in commercial drone adoption, with the global sector projected to expand from roughly $30 billion in 2024 to more than $54 billion by 2030 as agencies and enterprises seek greater operational visibility and risk reduction.